Skip to main content
. Author manuscript; available in PMC: 2015 Jan 16.
Published in final edited form as: Cell. 2014 Jan 16;156(0):317–331. doi: 10.1016/j.cell.2013.12.010

Figure 6. Ferroptosis Suppresses Tumor Growth in a Xenograft Mouse Model.

Figure 6

(A) Upregulation of PTGS2 expression upon erastin and (1S, 3R)-RSL3 treatments.

(B) PTGS2 expression was induced by PE, (1S, 3R)-RSL3, and siGPX4, but not by PE with Vit. E, (1R, 3R)-RSL3, and siDeath.

(C) (1S, 3R)-RSL3 inhibited tumor formation and tumor progression through induction of ferroptosis as demonstrated by upregulation of PTGS2 in the tumors. (1S, 3R)-RSL3 was administered s.c. twice a week for 2 weeks.

(D) PE showed efficacy in preventing HT-1080 tumor formation in a mouse xenograft model. The left view shows the structure of PE. The middle view is a mouse liver microsome assay demonstrating improved metabolic stability of PE over erastin. Midazolam was used as a positive control for metabolic degradation. The right view shows images representative of tumors in live mice from each treatment group. PE was delivered s.c. twice a week for 1 week and then delivered through tail vein injection once every other day for 6 days.

(E) Pharmacodynamics of PE and (1S, 3R)-RSL3 in the mouse liver tissue.

Bar graphs in (B), (C), and (E) represent mean ± SD (n = 3). In (C) and (D), the lines in the tumor volume plots indicate mean of nine data points. *p < 0.05; **p < 0.01. See also Figure S6 and Table S4.